On May 15, 2025, Protagenic Therapeutics, Inc. completed a merger by acquiring 100% of Phytanix Bio, issuing approximately 117,690 shares of common stock and various preferred shares in the process. The transaction was part of a Share Exchange Agreement with Alterola Biotech Inc. and EMC2 Capital LLC, and is significant as it allows Protagenic to expand its portfolio.